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Abstract
Background: Poly (ADP-ribose) polymerase (PARP) inhibitors are extensively studied and used as anti-
cancer drugs, as single agents or in combination with other therapies. Most radiotracers developed to date
have been chosen on the basis of strong PARP1–3 affinity. Herein, we propose to study AZD2461, a
PARP inhibitor with lower affinity towardsPARP3, and to investigate its potential for PARP targeting in vivo.
Methods: Using the Cu-mediated 18F-fluorodeboronation of a carefully designed radiolabelling
precursor, we accessed the 18F-labelled isotopologue of the PARP inhibitor AZD2461. Cell
uptake of [18F]AZD2461 in vitro was assessed in a range of pancreatic cell lines (PSN-1, PANC-
1, CFPAC-1 and AsPC-1) to assess PARP expression and in vivo in xenograft-bearing mice.
Blocking experiments were performed with both olaparib and AZD2461.
Results: [18F]AZD2461 was efficiently radiolabelled via both manual and automated procedures
(9 % ± 3 % and 3 % ± 1 % activity yields non-decay corrected). [18F]AZD2461 was taken up
in vivo in PARP1-expressing tumours, and the highest uptake was observed for PSN-1 cells
(7.34 ± 1.16 %ID/g). In vitro blocking experiments showed a lesser ability of olaparib to reduce
[18F]AZD2461 binding, indicating a difference in selectivity between olaparib and AZD2461.
Conclusion: Taken together, we show the importance of screening the PARP selectivity profile of
radiolabelled PARP inhibitors for use as PET imaging agents.
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Background
Genomic instability in cancerous tissues is increased as a
result of oncogenic and replicative stress, exogenous
genotoxic insults and tumour-specific DNA repair defects
[1]. Manipulating genomic instability can therefore provide
therapeutic opportunities, and inhibitors of DNA damage
repair enzymes have been extensively explored as anti-
cancer drugs [2]. Among these, poly (ADP-ribose) polymer-
ase (PARP) inhibitors have advanced furthest in the clinic.
Selective PARP inhibitors act on PARP1, PARP2 and
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Key Points Question: Can an isotopologue of the PARP inhibitor AZD2461
be used as an imaging agent of PARP expression in tumours in vivo?
Pertinent findings: Selectivity of radiolabelled PARP inhibitors is
important when evaluating tumour uptake.
Implications for patient care: Careful consideration of selectivity
patterns is needed when evaluating radiolabelled PARP inhibitors as
pharmacokinetic and/or pharmacodynamic biomarker.
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PARP3, all members of the 17-member PARP enzyme
family, also referred to as ART diphtheria toxin-like
(ARTD) enzymes, which also includes Tankyrase-1 and -2.
PARP1–3 bind to single-strand damaged DNA and play an
important role in its repair via the base excision repair (BER)
pathway. PARP inhibitors, such as olaparib (Lynparza),
niraparib (Zejula) and rucaparib (Rubraca) reduce catalytic
activity and interfere with the ability of the enzyme to
dislodge from DNA [3, 4]. They have been extensively
studied as single agents and radiation sensitizers and are
especially effective in tumours with defects in homologous
recombination (HR) DNA damage repair (DDR), such as
mutations in BReast CAncer gene (BRCA) [5, 6]. The
potential of PARP inhibitors was first shown in breast cancer
associated (BRCA)-deficient cancer such as breast or
ovarian cancer [7]. Olaparib (ku-0059436, AZ2281,
Lynparza®) was the first FDA approved oral potent PARP
inhibitor that inhibits PARP isoforms 1 and 2 and, to a lesser
extent, PARP3 [8]. To date, more than 100 clinical trials are
currently ongoing utilizing olaparib therapy as a single agent
or as a combination with chemo-, immuno- and radionuclide
therapies. In these clinical trials, interruption of the treatment
was mainly due to tumour progression, thought to be closely
related to emerging drug resistance [9]. Resistance to PARP
therapies is common, but not clearly understood. Reports
have shown that between 30 and 70 % of treated patients
having DDR machinery (HR) defects are not responsive to
PARP inhibitor therapy [10]. One of the mechanisms
thought to be involved in PARP inhibitor resistance is
overexpression of Abcb1a and Abcb1b genes encoding
efflux membrane transporter P-glycoprotein (P-gp). Studies
have shown overexpression of these genes in BRCA1- and
BRCA2-deficient mouse mammary tumours which is
thought to be associated with resistance to olaparib in this
model [11, 12].
Positron emission tomography (PET) is a powerful diag-
nostic tool providing molecular and functional information,
based on compounds radiolabelled with positron-emitting
radionuclides, such as 11C or 18F. PET imaging, an extremely
sensitive, non-invasive technique that is able to provide real-
time information, has proven to be a very useful tool for
measuring PARP expression and the pharmacokinetics and
dynamics of radiolabelled PARP inhibitors in vivo [13, 14].
Fluorine-18 is the most widely used PET radionuclide due to its
appropriate half-life (t1/2 = 109.8 min), good spatial resolution
and—most importantly—due to the stability of the C–F bond
[15, 16]. A number of groups have demonstrated the potential
of 18F-labelled PARP inhibitors in preclinical studies [17–20],
reviewed in [13] and [14]. [18F]PARPi is a 18F-labelled PARP
structurally related to olaparib [21]. To date, together with the
rucaparib-related tracer [18F]FTT, it is one of the few labelled
PARP inhibitors whose structure remains closely related to the
native inhibitor that has been investigated in clinical trials [20,
22]. While other labelled compounds have been investigated,
such as [18F]BO or [18F]PARPi-FL, few radiotracers have been
studied for their PARP PET imaging potential with a view to
assess a different PARP isoform interaction profile [23–25]. A
radiolabelled PARP inhibitor that possesses a different PARP
inhibitory profile may allow for a better understanding of
PARP expression in vivo.
The PARP inhibitor AZD2461, a structural variant of
olaparib, was developed in part to address the limitations of
PARP resistance mechanism and bone marrow toxicity (Fig. 1)
[26]. AZD2461 has been shown to have a different PARP
enzyme catalytic inhibitory profile than olaparib, in particular a
lower affinity for PARP3, as well as being a poor P-gp
substrate. A radiolabelled isotopologue of AZD2461 offers the
ability to investigate the role of PARP3 in DDR and more
specifically PARP imaging, as well as a wider range of
possibilities when developing new compounds that possess
different PARP specificity. In 2019, Mach and co-workers
described a radiofluorinated compound that was structurally
related to AZD2461 obtained through classic 18F-radiochem-
istry [27]. Although bearing similar backbone structure,
deviation from parent compound and subsequent lack of
knowledge regarding its interaction with PARP1–3 limits the
utility of this compound for PET imaging.
Here, we describe the radiofluorination of [18F]AZD2461
via Cu-mediated 18F-fluorodeboronation to result in an
isotopologue. We report on the ability of this radiotracer
for PARP imaging in PARP-expressing cell model and
in vivo in a xenograft tumour mouse model of pancreatic
cancer. Our study aimed at providing an insight into the
importance of the PARP selectivity profile for PARP
imaging using PET and revealed a marked difference in
specificity between AZD2461 and olaparib.
Methods
Full materials and methods are presented in the supplemental
information accompanying this manuscript.
Synthesis
[18F]AZD2461 was radiolabelled via the Cu-mediated 18F-
fluorodeboronation of the corresponding boronic ester
precursor (Fig. 2), using previously published methodolo-
gies, with minor modifications [17]. The corresponding
proto-deborylated side-product and the cold, non-
radiolabelled reference, AZD2461, were synthesised via a
similar pathway (Figs. 1 and 2). [18F]AZD2461 was also
obtained via a fully automated method, using a previously
described procedure, and then applied for [18F]olaparib [28].
See Supplemental Information for a full description of both
radiosyntheses.
In Vitro Evaluation
Pancreatic ductal adenocarcinoma (PDAC) cell lines PSN-1,
PANC-1, CFPAC-1 and AsPC-1 were originally purchased
from ATCC. Cells were cultured in Dulbecco’s Modified
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Eagle Medium (DMEM), supplemented with 10 % foetal
bovine serum (FBS), 2 mM L-glutamine, 100 units/ml
penicillin and 0.1 mg/ml streptomycin, in a 37 °C environ-
ment containing 5 % CO2. Cells were authenticated by the
provider, and their identity was corroborated by STR
profiling. The cumulative length of culture was less than
3 months following retrieval from liquid nitrogen storage.
Cells were tested regularly to confirm the absence of
mycoplasma contamination.
The ability of AZD2461, a protonated version, and
olaparib (compounds 1, 2 and 3) to inhibit PARP1, 2 and
3 was assessed using a cell-free chemiluminescent assay kit,
evaluating the inhibition of enzyme-mediated PARylation of
histones (cat. No 80551, BPS Bioscience), as per the
manufacturer’s instructions. Briefly, 96 well-assay plates
were coated with histone proteins, washed and blocked at
room temperature for 1 h. Next, the ribosylation reaction
mixture containing the biotinylated enzyme substrate was
added to the plate, followed by serial dilutions of the
appropriate inhibitor. The reaction was initiated with the
addition of the specific PARP enzyme (PARP1–3). Finally,
the plate was treated with streptavidin-HRP followed by the
HRP substrate to produce chemiluminescence that was
measured in a plate reader (Tecan Infinite M200 Pro). All
statistical analyses and non-linear regressions were per-
formed using GraphPad Prism v8 (GraphPad Software).
Relative PARP1 levels were determined using Western
blot. In brief, total cell lysates from 1 × 107 cells (AsPC-1,
CFPAC-1, PANC-1 and PSN-1) were prepared using
standard RIPA lysis buffer (50 mM Tris, pH 8, 1 % NP40,
0.5 % sodium deoxycholate, 0.1 % sodium dodecyl sulphate,
150 mM sodium chloride plus cOmplete™ protease inhibitor
cocktail [Sigma-Aldrich]). The cell lysates were isolated by
centrifugation after lysis through a 21G hypodermic syringe.
Fifteen micrograms of total protein were run on a 4–12 %
Bis-Tris MOPS gel (Novex) and transferred to a PVDF
membrane (Invitrogen iBlot-2). The blots were blocked in
5 % BSA at room temperature for 1 h and exposed to a
1:500 dilution of anti-PARP1 antibody (Atlas HPA045168)
at 4 °C overnight, followed by a 1:3000 dilution of the
secondary goat anti-rabbit-HRP antibody (R&D Systems
HAF008) at room temperature for 1 h. Sample loading
controls were performed using an anti-beta actin antibody
(Abcam ab8227). The blots were developed using the
Fig. 1. a Structures and b PARP1, 2 and 3 inhibitory profiles of AZD2461 1, proto-deborylated side-product AZD2461-H 2 and
olaparib 3. The PARP inhibitor Rucaparib was added as for comparison.
Fig. 2. Synthesis of [18F]AZD2461 from SEM-protected boronate precursor 4 via Cu-mediated radiofluorination.
Guibbal F. et al.: [18F]AZD2461 PET imaging
SuperSignal West Pico PLUS Chemiluminescent Substrate
kit (#34580, Thermo Scientific) and exposed to a Li-Cor
3600 Blot Scanner.
To evaluate PARP-mediated cell uptake, aliquots of 5 × 105
cells per well were seeded in 24 well plates and allowed to
adhere overnight. Cells were exposed to [18F]AZD2461
(50 kBq/well) for 1 h at 37 °C. After washing, cells were lysed
(0.1 M NaOH, 10 min), and cell-associated 18F was assessed
using an automated gamma counter (PerkinElmer Wizard2
2480). To determine the specificity of cell uptake, an excess of
cold, unlabelled olaparib or AZD2461 (100 μM) was co-
incubated with the radiolabelled compound.
In Vivo Evaluation
All animal procedures were performed in accordance with
the UK Animals (Scientific Procedures) Act 1986 and with
local ethical committee approval. Tumour xenografts were
generated by subcutaneous injection of PSN-1, PANC-1,
CFPAC-1 or AsPC-1 cell suspensions in the hind flank of
Balb/c nu/nu mice. A single tumour was implanted per
animal. Tumour xenografts were allowed to grow to a size of
200–400 mm3 before subsequent procedures.
PET/CT images were acquired 1 h after an intravenous bolus
administration of [18F]AZD2461 (5–6 MBq) using a
VECTor4CT scanner (MILabs, Utrecht, the Netherlands).
Animals were anaesthetised by 4 % isoflurane gas (0.5 L/min
O2) and maintained at 2 % and 37 °C throughout the imaging
session. The temperature of the animals was maintained at
37 °C, using a custom-built mouse cradle. Image acquisition was
performed in 10 min using a 1.8-mm pinhole collimator. Whole-
body CT images were acquired at a tube setting of 55 kVp,
0.19 mA and 20 ms per view, for anatomical reference and
attenuation correction. Reconstruction of both CT and PET
images was performed with the MILabs reconstruction analysis
using a γ-ray energy window of 467–571 keV (background
weight 2.5 %), 0.6 mm3 voxel size, 128 subsets and 5 iterations
using the manufacturer’s SROSEM reconstruction type. PET
images were each registered to CT and then attenuation
corrected. Images were calibrated by imaging a phantom
containing a fluorine-18 standard solution and analysed using
PMod software package (Version 3.807, PMOD Technologies).
Biodistribution studies, where selected tissues were harvested,
were performed immediately after imaging. Some animals were
also intravenously administered an excess of cold, unlabelled
olaparib or AZD2461 (0.02 mg, 100 μL) 30 min before
[18F]AZD2461 injection, to evaluate the specificity of tumour
uptake. The amount of [18F]AZD2461 uptake in selected tissue
was determined and reported as a percentage of the injected dose
per gram of tissue (%ID/g). Three mice were utilised per group.
Statistical Analysis
All statistical analyses and nonlinear regression were
performed using GraphPad Prism v8 (GraphPad Software,
San Diego, CA, USA). Data were tested for normality and
analysed by 2-way or 1-way analysis of variance (ANOVA),
with Tukey’s post-tests, as appropriate, to calculate the
significance of differences between groups. All data were
obtained at least in triplicate and results reported as mean ±
standard deviation, unless indicated otherwise.
Results
[18F]AZD261 Labelling via Copper-Mediated 18F-
Fluorodeboronation of Aryl Boronate Ester
[18F]AZD2461 was prepared via copper-mediated 18F-
fluorodeboronation of a protected boronic pinacol ester
precursor (Fig. 2, Supplemental Fig. 1) in an activity yield
of 9 % ± 3 % (non-decay corrected, n = 5, total synthesis
time = 135 min from dried [18F]fluoride to reformulated
compound) with molar activities up to 17 GBq/μmol and
radiochemical purity 9 99 %. As shown in our previously
reported studies [17, 29], free nitrogens can be detrimental to
Cu-mediated radiofluorination. Since the boronic ester
precursor used here bears a phtalazinone, appropriate N-[2-
(trimethylsilyl)ethoxymethyl] (SEM) protection was per-
formed as predicted by previous screening experiments
[17]. Conditions previously optimised for radiolabelling of
[18F]olaparib were used here for 18F-fluorodeboronation of
[ 1 8F ]AZD2461 . The coppe r ca t a lys t fo r 1 8F -
f luorodeboronat ion chosen for th is s tudy was
Cu(OTf)2(impy)4 (impy, imidazo[1,2-b]pyridazine). 1,3-Di-
methyl-2-imidazolidinone (DMI) was demonstrated to be
compatible and suitable for 18F-radiofluorination. More
importantly, an undesired side-product—due to
protodeboronation of the precursor—could be separated
from the desired radiotracer (Supplemental Fig. 4) and
allowed isolation of the pure [18F]AZD2461 (Supplemental
Figs. 5, 6). The final tracer was reformulated in 10 %
dimethyl sulfoxide (DMSO) in phosphate-buffered saline
(PBS), suitable for subsequent in vitro and in vivo experi-
ments (600 MBq/ml). A fully automated procedure, using an
Eckert & Ziegler Modular-Lab platform, allowed isolation of
[18F]AZD2461 in an activity yield of 3 % ± 1 % (non-decay
corrected, n = 4, total synthesis time = 120 min from dried
[18F]fluoride to reformulated compound) with molar activ-
ities up to 237 GBq/μmol and radiochemical purity 9 99 %.
[18F]olaparib was synthesised, for comparison, as described
in our previous study [17].
[18F]AZD2461 Is Taken Up Specifically in PARP1
Expressing Xenografts In Vivo
To investigate PARP targeting in tumour tissue, mice
bearing subcutaneous xenografts were injected intravenously
with [18F]AZD2461. The biodistribution and excretion
pathway was similar to that observed in our previously
reported study with [18F]olaparib, with [18F]AZD2461
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showing lower uptake in liver, while splenic uptake values
are higher compared with [18F]olaparib, at the time point
investigated (Fig. 3). Uptake in organs expressing PARP1, 2
and 3 such as the spleen, bone and the pancreas was
observed, as well as hepatobiliary excretion. The
biodistribution profile of [18F]AZD2461 observed in all
normal tissues was similar for mice bearing AsPC-1,
CFPAC-1 or PANC-1 xenografts (P 9 0.05). Uptake of
[18F]AZD2461 in PARP1-expressing xenografts was 2.39 ±
0.65, 3.04 ± 1.37 and 3.50 ± 0.91 %ID/g for AsPC-1,
CFPAC-1 and PANC-1, respectively, 1 h after intravenous
bolus injection. The highest uptake in tumour was observed
in PSN-1 xenografts (7.34 ± 1.16%ID/g) and was signifi-
cantly higher than that in AsPC-1, CFPAC-1 and PANC-1
xenografts (P = 0.0019, 0.0047 and 0.0092, respectively),
correlating with higher PARP1 expression levels obtained
by Western blot. To investigate the specificity of tumour
uptake, injection of an excess of cold, unlabelled olaparib
and AZD2461 were performed in mice bearing PSN-1
xenografts. While an excess of olaparib was able to
efficiently block tumour uptake of [18F]AZD2461 (1.55 ±
0.51 %ID/g, P = 0.0022), the same amount of cold
AZD2461 only blocked [18F]AZD2461 accumulation in
tumours to 3.21 ± 0.70 %ID/g (P = 0.0204, Fig. 4).
[18F]AZD2461 Is Taken up by PARP-Expressing
PSN-1 Cells, with Off-Target Specific Binding
AZD2461 inhibited PARP1–3 enzymatic activity in line
with previously reported values (Fig. 1). Proto-deborylated
side-product 2 showed an ability to inhibit all isoforms
tested. To assess PARP targeting, PARP-expressing pancre-
atic tumour cells (PSN-1) were exposed to [18F]AZD2461 or
[18F]olaparib for 30 min. Both radiotracers were efficiently
taken up in PSN-1 cells (Fig. 5). Uptake of [18F]olaparib was
similar to that reported in our previously reported study [17].
Blocking experiments showed that addition of an excess of
non-radioactive olaparib or AZD2461 was able to efficiently
block uptake of [18F]olaparib in PSN-1 cells, lowering
uptake to a 10 % of uptake in otherwise naïve cells (P G
0.0001). In contrast, while [18F]AZD2461 was efficiently
taken up in PSN-1 cells and excess of non-radioactive
AZD2461 was able to efficiently reduce uptake to 25 % of
initial binding (P = 0.0022), the same excess of cold olaparib
was only able to reduce uptake of [18F]AZD2461 to a mere
70 % of native binding (P = 0.024).
Discussion
PARP enzymes play a crucial role in DNA damage repair. A
wide range of highly selective and potent inhibitors of PARP
have been developed (olaparib, rucaparib, talazoparib,
veliparib, niraparib, and a plethora of others) and studied
in clinical trials for their ability to compete with NAD+
binding as the PARP substrate. However, due to inhibition
of the PARP3 isoform, expressed in a.o. bone marrow, may
lead to haematological toxicity. Therefore, PARP inhibitors
with different PARP inhibition profiles, such as AZD2461,
with less ability to inhibit PARP-3, have also been evaluated
as an alternative to compounds currently in clinical use.
In our previously reported study, we showed the strong
potential of [18F]olaparib, a radio-isotopologue of the
AstraZeneca compound olaparib, for PET imaging of PARP
in a mouse model of human PDAC [17]. Other studies have
demonstrated the ability of a range of radiolabelled PARP
compounds to monitor PARP expression in a variety of
preclinical cancer models [17–20]. However, among the 17-
member PARP family, most studies focus on the implication
of PARP1, but other isoforms are generally overlooked. As
demonstrated by earlier reports [30], PARP inhibitors have
different binding towards the 17 isoforms of PARP. Carney
and co-workers described the use of a radiolabelled PARP
binding agent (which catalytically inhibits, and therefore
binds to, PARP1, 2 and, to a lesser extent, PARP3, 6, 7 and
8 and TNKS2). Hence, it is important to underline that the
catalytic inhibition spectra for various PARP inhibitors (e.g.
rucaparib, talazoparib, olaparib or AZD2461) are different
and by extension their binding affinities to the various PARP
isoforms. Our in vitro results show that our cell lines used
have high PARP1 expression (Fig. 3c) and therefore
represent good models to investigate AZD2461 for PET
imaging of PARP expressing tumours.
18F-radiolabelling of neutral (hetero)arenes often requires
a robust synthetic approach in order to secure radiosynthesis.
Most studies rely on aliphatic radiolabelling or the use of
radiolabelled prosthetic groups to produce radiotracers in
reasonable activity yields (AY) and molar activities (Am)
[21, 23]. However, as previously demonstrated with
[18F]olaparib, in this study, we were able to efficiently
radiolabel [18F]AZD2461 using the Cu-mediated
radiofluorination method, originally developed by Tredwell
et al. [31]. This process allows for the straightforward one-
pot or two-step radiolabelling of a boronic ester precursor,
for which retrosynthesis needs to be carefully planned. This
method was shown to be translatable and automated,
allowing high activity yield and molar activities (AY and
Am up to 4 % and 237 GBq/μmol, respectively, full details
are displayed in Supplemental Information). One of the
major side-products formed during reaction course is the
undesired proto-deborylated compound 2 (Fig. 1) during
18F-fluorodeboronation of radiolabelling precursor 4. Our
in vitro data showed that 2 is a potential inhibitor of PARP1,
2 and 3 isoforms with similar IC50 compared with
[19F]AZD2461 1. This underlines the necessity of HPLC
separation to avoid any contamination [17, 32]. With 19F
references 1 and 2 in hand, we were able to demonstrate the
efficient separation of both products by semi-preparative and
analytical radio-HPLC, affording a difference in retention
time of 3 min between both products. The final reformulated
dose (between 100 and 600 MBq) were found suitable for
following in vitro and in vivo experiments.
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Fig. 3. a Biodistribution in mice bearing PSN-1, CFPAC-1, AsPC-1 or PANC-1 tumour xenografts, at 1 h post-injection of
[18F]AZD2461. b Tumour uptake and tumour/pancreas ratios in PSN-1, CFPAC-1, AsPC-1 and PANC-1 xenografts 1 h post-
injection c Western blot probing for PARP-1 in PSN-1, PANC-1, CFPAC-1 and AsPC-1 cell lines. (**P G 0.01).
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We then moved to investigate the ability of our
radiotracer to target PARP expression in vivo in a range of
tumour xenograft models of pancreatic cancer (Fig. 5).
Comparing olaparib and AZD2461, highly similar metabo-
lism and catabolism were observed, unsurprising given they
possess very close chemical structures, yet bind differen-
tially to the different PARP isoforms. This underlines the
importance of using radiotracers to study structurally related
inhibitors that bear similar physicochemical and elimination
properties. Both [18F]olaparib and [18F]AZD2461 showed
high tumour uptake in PDAC xenograft tissue. The
specificity of the uptake of [18F]olaparib, demonstrated by
the ability of an excess of cold olaparib to significantly
block tumour uptake, but AZD2461 only able to block
uptake of its radio-isotopologue to a lesser extent, led us to
conclude that differences in target binding or specificity
might be responsible. Follow-up in vitro experiments
showed high uptake of both radiotracers, correlating with
the high level of PARP expression in PSN-1 cells. Non-
radioactive olaparib and AZD2461 were both able to reduce
uptake of [18F]olaparib to a minimum of 10 %, corroborating
the high degree of specific binding of olaparib, as demon-
strated in our previous report [17]. While similarly high cell
association was observed for [18F]AZD2461 in the same cell
line, blocking showed a markedly reduced ability of olaparib
to block cell uptake, contrary to an excess of AZD2461.
While our previous in vivo experiments showed the lesser
ability of non-radioactive AZD2461 to block [18F]AZD2461
tumour uptake compared with olaparib, variations in
pharmacokinetics between the two inhibitors may be
responsible for the differences observed. It is important to
underline that there is no complete blocking with
[18F]AZD2461 compared with [18F]olaparib using non-
radioactive olaparib or AZD2461. Taken together, this
Fig. 4. Blocking experiments performed in PSN-1 xenograft-bearing mice. Cold, unlabelled AZD2461 or olaparib (20 μg) was
administered intravenously, 30 min prior to [18F]AZD2461. a Biodistribution, b tumour uptake.
Fig. 5. In vitro uptake of [18F]AZD2461 and [18F]olaparib in PSN-1 cells, 30 min after addition of [18F]AZD2461. An excess of
cold, unlabelled olaparib or AZD2461 was added (100 μM). (* P G 0.05, ** P G 0.01, **** P G 0.0001).
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suggests the ability of AZD2461 to bind to alternative
targets in addition to those engaged by olaparib, although the
precise targets have not been yet identified. While many
studies describe the use of labelled inhibitors or associated
variants [20, 23, 24, 27, 33], our study emphasises the
critical evaluation of different PARP isoforms or alternative
binding epitopes for PET imaging of PARP expression.
Reilly and co-workers have shown the use of an 18F-labelled
variant of AZD2461 [27]. However, differences in com-
pound structures, PARP isoforms studied or model used
make for a challenging direct comparison. When developing
a DNA damage response PET imaging agent and in order to
completely understand its target engagement, we
hypothesise that non-PARP1 and PARP2 effects should also
be considered to understand how tumour uptake of a
radiolabelled compound relates to PARP biology. Con-
versely, any radiolabelled compound that only binds to
PARP1 and 2 cannot be used to fully assess specific target
engagement of an inhibitor also binding to, e.g. PARP3 or
TNKS2. Even though, these results do not directly relate
difference in specificity with PARP profile, we have shown
that small variations in structure not known to be involved in
PARP binding may lead to significant differences in binding
selectivity and specificity in vivo and in vitro; these
differences may underline the relative potential of the
imaging agent as a diagnostic tool.
Conclusion
Here, we have shown the ability of [18F]AZD2461 to target
PARP expression in an in vivo mouse model of pancreatic
cancer. While [18F]olaparib uptake was highly specific, we
underline the difference in target binding with
[18F]AZD2461 which shows its lesser ability to be utilised
as a PARP imaging agent. As a consequence, PARP PET
imaging, involving PARP radiolabelled inhibitors, requires
knowledge of the binding profile and potential alternative
targets in order to understand the biological information that
can be obtained from these powerful imaging tools.
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